This assay quantifies the bioactivity of immune complexes in autoimmune diseases, indicating its potential for better diagnosis.
The FcγRIIIA-reporter assay enables precise quantification of pathogenic bioactivity of IC in various systemic autoimmune diseases, providing complementary information to existing serological markers.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: